ClinicalTrials.gg
CompletedNCT04901962Updated Jan 5, 2023

Study to Evaluate Made-to-measure Compression Garments

An interventional study of JOBST® Confidence compression garments in Lymphedema, sponsored by BSN Medical GmbH. Completed at 4 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-05.

Sponsored by BSN Medical GmbH · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The primary objective is to collect real-life data to evaluate the clinical performance and safety of innovative, made-to-measure, flat knitted, CE-marked compression garments for daytime treatment of leg or arm lymphedema (ISL stage I-II) in daily routine by analysing performance parameters and safety parameters reported during the investigation.

Read the detailed description

The secondary objective is to evaluate (1) patients' quality of life QoL before and after having tested JOBST Confidence and (2) patient satisfaction focussing on patient reported outcomes of previously worn garments and JOBST® Confidence by analysing patient questionnaires parameters completed at the beginning and in the end of the wearing period.

02

Conditions studied

  • Lymphedema

Browse trials for

03

In context

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

This study's enrollment of 99 is above the median of 52 across 369 interventional studies indexed under Lymphedema.

Browse Lymphedema studies →

Lead sponsor

BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form
  2. Men, women or diverse aged 18 years or up to 70 years with full legal competence
  3. Patient is mentally and physically able to participate in the study
  4. Capability to understand the subject information and to provide conscious informed consent
  5. Capability and willingness to follow protocol requirements
  6. All female or diverse subjects of must agree to use a reliable method of with a Pearl-Index of less than 1% per year when used consistently and correctly* (*such as hormone implants,injectables, combined oral contraceptives (combined gestagen-estrogen pills), some intra uterine devices (IUDs), surgically sterility (hysterectomy or tubal ligation), sexual abstinence or vasectomized partner for at least 4 weeks)
  7. Mild to moderate lymphedema of the lower and/or upper extremities (ISL stage I or II)
  8. Indication and possibility of treatment with a flat-knitted compression garment during the day
  9. Patients who are familiar with wearing compression garments
  10. Indicated Complete Decongestive Therapy Phase II (Maintenance phase)
  11. Willingness to wear the study product at least 5 days a week for at least 6 hours a day

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women or diverse subjects
  2. Alcohol abuse (mentioned by the patient and/or suspected by the investigator)
  3. Drug abuse (mentioned by the patient and/or suspected by the investigator)
  4. Patients who need a different compression class (higher or lower than CCL 2)
  5. Pronounced skin folds
  6. Pronounced shape distortions
  7. cG (lymphatic measure of the thigh) >90 cm for AG stocking
  8. Indicated Complete Decongestive Therapy Phase I
  9. Known allergy or intolerance to one or more components of the product
  10. Advanced arterial insufficiency including ischemia
  11. Uncontrolled congestive heart failure
  12. Untreated septic phlebitis
  13. Phlegmasia coerulea dolens
  14. Immobility (confinement to bed).
  15. Conditions in which increased venous and lymphatic return is not desired.
  16. Weeping dermatosis
  17. Cutaneous infections
  18. Severely compromised skin sensibility and impaired sensitivity of the limb
  19. Advanced peripheral neuropathy
  20. Rheumatoid arthritis
  21. Complex regional pain syndrome (CRPS, M. Sudeck)
  22. Malignant lymphedema
  23. Gangrene
  24. Sponsors or manufacturers staff
  25. Open wounds in the test area
  26. Diuretics, except low doses for treatment of hypertension (≤ 12.5 mg Hydrochlorothiazide)
  27. Nephrotic syndrome
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    JOBST® Confidence compression garments

    The CE-marked class I medical devices JOBST® Confidence compression garments for lower and upper extremities will be tested under routine conditions according to their selected intended use. Subjects will be treated with either thigh-high compression stockings (AG) or arm compression garments without hand part (CG1), depending on their indication.

    Device: JOBST® Confidence compression garments

Interventions

  • DeviceJOBST® Confidence compression garments

    JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.

06

What researchers measure

Primary outcomes

  1. Clinical performance: circumference of the edema

    Circumference measurements at selected points of the limb (taken manually using measuring tape) \[cm\]

    Time frame: change from baseline after a treatment duration of 7, 14, and 21 days

  2. Clinical performance: edema status

    Evaluation of edema (visual inspection and palpitation) according to standardized criteria

    Time frame: change from baseline after a treatment duration of 7, 14, and 21 days

Secondary outcomes

  1. Quality of Life assessed by patient questionnaire

    extend of restrictions regarding work due to the lymphoedema (indicated on a 5-point scale)

    Time frame: assessed before treatment and after 21 days of treatments with JC

  2. Quality of Life assessed by patient questionnaire

    extend of restrictions regarding leisure time due to the lymphoedema (indicated on a 5-point scale)

    Time frame: assessed before treatment and after 21 days of treatments with JC

  3. Quality of Life assessed by patient questionnaire

    extend of restrictions regarding psychological well-being due to the lymphoedema (indicated on a 5-point scale)

    Time frame: assessed before treatment and after 21 days of treatments with JC

  4. Patient satisfaction assessed by patient questionnaire

    Comparison of patient reported outcomes regarding previously worn compressions garments and JC

    Time frame: assessed before treatment and after 21 days of treatments with JC

07

Study locations

4 sites
  • Gefäßkrankheiten Rhein-Ruhr
    Essen, Nordrhein-Westfalen 45131, Germany
  • Dr. Hans-Walter Fiedler
    Werl, North Rhine-Westphalia 59457, Germany
  • Praxis für Innere Medizin und Gefäßkrankheiten
    Halle (Saale), Sachsen-Anhalt 06108, Germany
  • Dr. med. Jörg Schleinitz Facharzt für Allgemeinmedizin
    Lützen, Sachsen-Anhalt 06686, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Dec 2022, 17 months.

Of 197 interventional studies with no phase under Lymphedema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 64. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2021
First posted
May 26, 2021
StartActual
Jul 21, 2021
Primary completionActual
Dec 22, 2022
CompletionActual
Dec 22, 2022
Last update
Jan 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04901962
Lead sponsor
BSN Medical GmbH
Responsible party
Sponsor
First posted
May 26, 2021
Start date
Jul 21, 2021
Primary completion
Dec 22, 2022
Completion
Dec 22, 2022
Last update
Jan 5, 2023

Study contacts

Tobias Hirsch, Dr. med.
principal investigator · Praxis für Innere Medizin und Gefäßkrankheiten

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion